Do Not Use Smartwatches, Rings That Claim To Measure Blood Sugar Without Needles, FDA Says
Portfolio Pulse from Vandana Singh
The FDA has issued a warning against the use of smartwatches and smart rings that claim to measure blood glucose levels without skin penetration, stating that no such devices have been approved. The warning includes devices from any manufacturer, despite ongoing efforts by companies like Apple Inc and Samsung Electronics to develop non-invasive blood glucose monitoring technology. Consumers and healthcare providers are advised to avoid these unapproved devices and report any issues through the MedWatch Voluntary Reporting Form.
February 22, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Apple Inc is mentioned as working on developing non-invasive blood glucose monitoring technology, which is still in the proof-of-concept stage and not expected to be market-ready for several years.
Apple's involvement in developing non-invasive blood glucose monitoring technology is significant, but the FDA's warning primarily affects consumer perception and regulatory compliance. Since the technology is not market-ready and still in development, the short-term impact on Apple's stock is likely neutral. However, investor confidence and public perception could be influenced by how Apple responds to regulatory guidelines and progresses with the technology.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Samsung Electronics is also developing non-invasive blood glucose monitoring technology, aiming to incorporate it into the Galaxy Ring. The FDA's warning affects all manufacturers claiming non-invasive blood glucose measurement capabilities.
Samsung Electronics' development of non-invasive blood glucose monitoring technology for the Galaxy Ring is noteworthy. The FDA's warning is a regulatory hurdle for all companies in this space, including Samsung. Given that the technology is still under development and not yet available to consumers, the short-term impact on Samsung's stock is likely neutral. The company's response to regulatory challenges and progress in technology development will be key factors for investors to watch.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70